mRNA-1647: Clinical Trials

6 completed, 1 active not recruiting, 1 terminated, 1 withdrawn. 5 Phase 2, 4 Phase 1, 1 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	5	Completed 3, Active not recruiting 1, Withdrawn 1
Phase 1	4	Completed 4
Phase 3	1	Terminated 1

Follow mRNA-1647: new trials by email Literature Review of mRNA-1647 trials Research Report on mRNA-1647

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients mRNA-1647, Placebo - Cytomegalovirus Infection	Phase 2	Withdrawn	ModernaTX, Inc.		2024-02-08	2024-03-15
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants. mRNA-1647, Placebo - Cytomegalovirus Infection	Phase 2	Active not recruiting	ModernaTX, Inc.	84	2023-04-05	2026-08-10
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age mRNA-1647, Placebo - Cytomegalovirus	Phase 1 / Phase 2	Completed	ModernaTX, Inc.	873	2022-11-07	2026-06-04
A Study of Modified mRNA Vaccines in Healthy Adults mRNA-1273, mRNA-1010, mRNA-1345 - SARS-CoV-2, Seasonal Influenza	Phase 1	Completed	ModernaTX, Inc.	308	2022-05-24	2026-03-12
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 mRNA-1647, Placebo - Cytomegalovirus Infection	Phase 1	Completed	ModernaTX, Inc.	9	2021-11-08	2023-09-11
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age mRNA-1647, Placebo - Cytomegalovirus Infection	Phase 3	Terminated	ModernaTX, Inc.	7454	2021-10-26	2025-12-15
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine mRNA-1647 - Cytomegalovirus Infection	Phase 2	Completed	ModernaTX, Inc.	135	2021-06-18	2026-02-02
Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults mRNA-1647, Placebo - Cytomegalovirus Infection	Phase 2	Completed	ModernaTX, Inc.	315	2020-01-09	2026-05-05
Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults mRNA-1647, mRNA-1443, Placebo - Cytomegalovirus Infection	Phase 1	Completed	ModernaTX, Inc.	181	2017-11-13	2021-01-15

Conditions studied

Cytomegalovirus Infections (8)  ·  Virus Diseases (7)  ·  DNA Virus Infections (5)  ·  Herpes Simplex (2)  ·  COVID-19 (1)  ·  Coronavirus Infections (1)  ·  Influenza, Human (1)

Sponsors

ModernaTX, Inc. (9)

Countries

United States (8)  ·  Canada (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Belgium (1)  ·  Estonia (1)  ·  Finland (1)  ·  France (1)  ·  Germany (1)  ·  Israel (1)  ·  Italy (1)  ·  Japan (1)  ·  Spain (1)

Results publications

PMID 38190492, PMID 36102707, PMID 37899366, PMID 38324766, PMID 38478705, PMID 38526054, PMID 40276503, PMID 41398408, PMID 41535296

NIH funding

2023 (1)